July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
3 citations
,
May 2024 in “Journal of Drug Delivery and Therapeutics” Aftimoon has potential health benefits for various diseases and could be integrated into modern healthcare.
June 2021 in “Current developments in nutrition” The LustrivaTM BH-002 supplement and hair serum improved women's hair, skin, and nail health and appearance.
14 citations
,
January 2005 in “Pediatric Dermatology” UVA1-light therapy successfully treated a child's skin condition, mycosis fungoides.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
3 citations
,
July 2025 in “British Journal of Dermatology” Cinainu is effective and safe for treating children's alopecia areata.
November 2022 in “CARDIOMETRY” A group has developed therapies that show promise for treating cancer and various other conditions.
January 2008 in “Zhonghua linchuang mianyi he biantai fanying zazhi” The treatment with Shunyou and prednisone is effective and safe for lupus nephritis.
Lamivudine might reverse hair graying and needs more research for potential treatments.
August 2025 in “Ophthalmic Plastic and Reconstructive Surgery” Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
April 2024 in “JMIR infodemiology” TikTok videos show that people with Lupus often discuss symptoms and their significant impact on mental health, face diagnostic delays, have mixed views on treatments, and feel isolated despite support.
14 citations
,
November 2018 in “Journal of drug delivery and therapeutics” Ethosomes are effective, safe carriers for delivering drugs through the skin.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
November 2024 in “Forensic Sciences” Understanding the Y chromosome is key to male health, aging, and developing diagnostic tools.
15 citations
,
February 2024 in “Journal of Dermatological Treatment” Dupilumab may help treat alopecia areata without needing high IgE levels.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
1 citations
,
April 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Tislelizumab can cause cutaneous lupus erythematosus.
2 citations
,
January 2014 in “Journal of Cytology & Histology” Rapamycin and anti-EGFR antibody reduce LAM/TSC cell migration and blood vessel growth in the uterus.
December 2023 in “Curēus” A woman with lupus had rare severe symptoms but improved with treatment.
February 1961 in “The Lancet” Some new drugs show potential for treating blood cancers but have serious side effects and need more research.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
May 2025 in “The Journal of Rheumatology” The project highlights the importance of early diagnosis and patient advocacy in managing Systemic Lupus Erythematosus.
July 2023 in “Journal of Ayub Medical College Abbottabad” A woman in Pakistan was diagnosed with Lupus Vasculitis and treated successfully.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)”